Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis

Maurizio Benucci,1 Francesca Bandinelli,1 Arianna Damiani,1 Francesca Li Gobbi,1 Maria Infantino,2 Valentina Grossi,2 Mariangela Manfredi2 1Rheumatology Unit, Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy; 2Immunology and Allergology Laboratory Unit, Hospital S. Giovanni d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Benucci M, Bandinelli F, Damiani A, Li Gobbi F, Infantino M, Grossi V, Manfredi M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Abatacept rheumatoid arthritis cardiovascular disease Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/3aa43a9014614bb9bea8139ec14303ef
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3aa43a9014614bb9bea8139ec14303ef
record_format	dspace
spelling	oai:doaj.org-article:3aa43a9014614bb9bea8139ec14303ef2021-12-02T00:32:57ZFactors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis1178-7031https://doaj.org/article/3aa43a9014614bb9bea8139ec14303ef2018-06-01T00:00:00Zhttps://www.dovepress.com/factors-correlated-with-the-improvement-of-endothelial-dysfunction-dur-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Maurizio Benucci,1 Francesca Bandinelli,1 Arianna Damiani,1 Francesca Li Gobbi,1 Maria Infantino,2 Valentina Grossi,2 Mariangela Manfredi2 1Rheumatology Unit, Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy; 2Immunology and Allergology Laboratory Unit, Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy Background: Rheumatoid arthritis patients are exposed to a high risk of cardiovascular morbidity and mortality even in the early phases of the disease. Methods: We evaluated carotid common carotid intimal media thickness (ccIMT) intimal thickness and brachial flow-mediated dilation (FMD) of 45 rheumatoid arthritis patients without known cardiovascular risk factors or heart disease on a stable dose of prednisone 5.2±1.2 mg/day and Methotrexate 11.5±2.1 mg at baseline (T0) and after 12 months (T1) of treatment with Abatacept 125 mg/week. The comparison between T0 and T1 (t- and Mann–Whitney test), correlation (Spearman r), and predictivity (linear regression) of FMD, ccIMT vs clinical and laboratory parameters (disease activity 28 score, tumor necrosis factor alpha [TNFα], interleukin-6, erythrocyte sedimentation rate, C-reactive protein (CRP), CD3+, CD3+/CD4+, CD3+/CD8+, CD19+(B), CD20+(B), NK CD3-CD56+CD16+, CD14+ HLA DR+, CD4+CD28+, CD4+CD28, rheumatoid factor IgM, IgA, RF IgG, anti-citrullinated peptide antibodies) were also evaluated. Results: During Abatacept treatment, ccIMT and FMD remained stable and disease activity 28 score, CRP, erythrocyte sedimentation rate, and interleukin-6 decreased significantly (p=0.0001, 0.002, 0.0002, 0.0001 respectively). At T0, only ccIMT resulted as correlated with baseline TNFα values (p=0.0245) in an inverse proportion. At T1, ccIMT correlated with CD3/CD8+ lymphocytes number (p=0.0351) and FMD with CRP (p=0.0075). In regression analysis, baseline ccIMT and FMD had a low predictivity for TNFα (p=0.011) and CRP (p=0.049) at T1, respectively. Conclusion: This study shows that the endothelial function remained stable during Abatacept treatment. Keywords: Abatacept, rheumatoid arthritis, cardiovascular diseaseBenucci MBandinelli FDamiani ALi Gobbi FInfantino MGrossi VManfredi MDove Medical PressarticleAbataceptrheumatoid arthritiscardiovascular diseasePathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 11, Pp 247-252 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Abatacept rheumatoid arthritis cardiovascular disease Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	Abatacept rheumatoid arthritis cardiovascular disease Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Benucci M Bandinelli F Damiani A Li Gobbi F Infantino M Grossi V Manfredi M Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis
description	Maurizio Benucci,1 Francesca Bandinelli,1 Arianna Damiani,1 Francesca Li Gobbi,1 Maria Infantino,2 Valentina Grossi,2 Mariangela Manfredi2 1Rheumatology Unit, Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy; 2Immunology and Allergology Laboratory Unit, Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy Background: Rheumatoid arthritis patients are exposed to a high risk of cardiovascular morbidity and mortality even in the early phases of the disease. Methods: We evaluated carotid common carotid intimal media thickness (ccIMT) intimal thickness and brachial flow-mediated dilation (FMD) of 45 rheumatoid arthritis patients without known cardiovascular risk factors or heart disease on a stable dose of prednisone 5.2±1.2 mg/day and Methotrexate 11.5±2.1 mg at baseline (T0) and after 12 months (T1) of treatment with Abatacept 125 mg/week. The comparison between T0 and T1 (t- and Mann–Whitney test), correlation (Spearman r), and predictivity (linear regression) of FMD, ccIMT vs clinical and laboratory parameters (disease activity 28 score, tumor necrosis factor alpha [TNFα], interleukin-6, erythrocyte sedimentation rate, C-reactive protein (CRP), CD3+, CD3+/CD4+, CD3+/CD8+, CD19+(B), CD20+(B), NK CD3-CD56+CD16+, CD14+ HLA DR+, CD4+CD28+, CD4+CD28, rheumatoid factor IgM, IgA, RF IgG, anti-citrullinated peptide antibodies) were also evaluated. Results: During Abatacept treatment, ccIMT and FMD remained stable and disease activity 28 score, CRP, erythrocyte sedimentation rate, and interleukin-6 decreased significantly (p=0.0001, 0.002, 0.0002, 0.0001 respectively). At T0, only ccIMT resulted as correlated with baseline TNFα values (p=0.0245) in an inverse proportion. At T1, ccIMT correlated with CD3/CD8+ lymphocytes number (p=0.0351) and FMD with CRP (p=0.0075). In regression analysis, baseline ccIMT and FMD had a low predictivity for TNFα (p=0.011) and CRP (p=0.049) at T1, respectively. Conclusion: This study shows that the endothelial function remained stable during Abatacept treatment. Keywords: Abatacept, rheumatoid arthritis, cardiovascular disease
format	article
author	Benucci M Bandinelli F Damiani A Li Gobbi F Infantino M Grossi V Manfredi M
author_facet	Benucci M Bandinelli F Damiani A Li Gobbi F Infantino M Grossi V Manfredi M
author_sort	Benucci M
title	Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis
title_short	Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis
title_full	Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis
title_fullStr	Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis
title_full_unstemmed	Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis
title_sort	factors correlated with the improvement of endothelial dysfunction during abatacept therapy in patients with rheumatoid arthritis
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/3aa43a9014614bb9bea8139ec14303ef
work_keys_str_mv	AT benuccim factorscorrelatedwiththeimprovementofendothelialdysfunctionduringabatacepttherapyinpatientswithrheumatoidarthritis AT bandinellif factorscorrelatedwiththeimprovementofendothelialdysfunctionduringabatacepttherapyinpatientswithrheumatoidarthritis AT damiania factorscorrelatedwiththeimprovementofendothelialdysfunctionduringabatacepttherapyinpatientswithrheumatoidarthritis AT ligobbif factorscorrelatedwiththeimprovementofendothelialdysfunctionduringabatacepttherapyinpatientswithrheumatoidarthritis AT infantinom factorscorrelatedwiththeimprovementofendothelialdysfunctionduringabatacepttherapyinpatientswithrheumatoidarthritis AT grossiv factorscorrelatedwiththeimprovementofendothelialdysfunctionduringabatacepttherapyinpatientswithrheumatoidarthritis AT manfredim factorscorrelatedwiththeimprovementofendothelialdysfunctionduringabatacepttherapyinpatientswithrheumatoidarthritis
_version_	1718403669110554624

Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis

Ejemplares similares